EBOS Group Limited (EBOS) notes the announcement by the Australian Competition and Consumer Commission (ACCC) today that it will not oppose the proposed acquisition of LifeHealthcare announced on 9 December 2021.
The transaction remains subject to satisfaction of certain conditions precedent and the parties continue to work diligently towards completion of the transaction, which is expected in FY22.
The ACCC will not oppose the proposed acquisition of Australian Pacific Health Supplies TopCo1 Pty Limited and its subsidiaries (Pacific Health Group) by EBOS Group Limited (ASX: EBO), through its subsidiary EBOS Medical Devices Australia Pty Limited.
EBOS and Pacific Health Group distribute a range of medical devices to private and public hospitals and to clinicians. Pacific Healt h Group also manufactures and distributes allografts through its Australian Biotechnologies business. In general, the majority of the parties’ offerings are complementary and not in direct competition.
A copy of the statement by the ACCC is attached.
Comments from our readers
No comments yet
Add your comment:
Related News:
SPK-30 advanced with strategic review of Digital Services
FPH 2026 Notice of Annual Meeting and Voting Form
CNU - Q4 FY26 Connections Update
SPK - Spark announces appointment of Chief Operating Officer
SKC - Asset Monetisation Programme Update - The Grand Hotel
VCT - Full year results date & investor webcast details
ANZ - Air New Zealand 2026 Annual Results Webcast Details
SKC - Asset Monetisation Programme Update
July 17th Morning Report
MEL - Meridian Energy monthly operating report for June 2026